{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:15:32Z","timestamp":1791274532112,"version":"4.1.0"},"reference-count":160,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/wnf.0b013e3181a91655","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T14:39:24Z","timestamp":1253889564000},"page":"277-289","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacotherapy of Addictive Disorders"],"prefix":"10.1097","volume":"32","author":[{"given":"Stephen","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Peselow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210203","first-page":"1157","article-title":"Cigarette smoking among adults-United States, 2006.","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pharmthera.2005.06.021","article-title":"Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences.","volume":"108","author":"Volkow","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"1","key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0749-3797(99)00032-X","article-title":"Self-report of delivery of clinical preventive services by U.S. physicians. Comparing specialty, gender, age, setting of practice, and area of practice.","volume":"17","author":"Ewing","year":"1999","journal-title":"Am j Prev Med"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15288\/jsa.1991.52.33","article-title":"The effectiveness of alcoholism screening in an ambulatory care setting.","volume":"52","author":"Fleming","year":"1991","journal-title":"J Stud Alcohol"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.biopsych.2004.06.018","article-title":"Contemporary addiction treatment: a review of systems problems for adults and adolescents.","volume":"56","author":"McLellan","year":"2004","journal-title":"Biol Psychiatry"},{"issue":"2","key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/ADM.0b013e318166af74","article-title":"The case for chronic disease management for addiction.","volume":"2","author":"Saitz","year":"2008","journal-title":"J Addict Med"},{"issue":"4","key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcomes evaluation.","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2005.06.010","article-title":"Medications development: successes and challenges.","volume":"108","author":"Vocci","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tips.2004.04.006","article-title":"Nicotinic acetylcholine receptors and the regulation of neuronal signaling.","volume":"25","author":"Dajas-Bailador","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1099420","article-title":"Nicotine activation of 4 receptors: sufficient for reward, tolerance, and sensitization.","volume":"306","author":"Tapper","year":"2004","journal-title":"Science"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0091-3057(01)00652-9","article-title":"Cellular mechanisms of nicotine addiction.","volume":"70","author":"Dani","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"issue":"4A","key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.01.015","article-title":"Neurobiology of nicotine addiction: implications for smoking cessation treatment.","volume":"121","author":"Benowitz","year":"2008","journal-title":"Am J Med"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3322\/canjclin.55.5.281","article-title":"Pharmacotherapy for nicotine dependence.","volume":"55","author":"Henningfield","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"4A","key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjmed.2008.01.016","article-title":"Update on pharmacologic options for smoking cessation treatment.","volume":"121","author":"Nides","year":"2008","journal-title":"Am J Med"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s002130000382","article-title":"A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler.","volume":"149","author":"West","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(24)38905-0","article-title":"Bupropion is a nicotinic antagonist.","volume":"295","author":"Slemmer","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"R20-8-20210203","first-page":"CD000031","article-title":"Antidepressants for smoking cessation.","author":"Hughes","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 2","key":"R21-8-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003495-200262002-00003","article-title":"Clinical efficacy of bupropion in the management of smoking cessation.","volume":"62","author":"Jorenby","year":"2002","journal-title":"Drugs"},{"key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1016\/j.bmcl.2005.08.035","article-title":"3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.","volume":"15","author":"Coe","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an 42 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an 42 vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"R26-8-20210203","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14622200500185298","article-title":"Nortriptyline for smoking cessation: a review.","volume":"7","author":"Hughes","year":"2005","journal-title":"Nicotine Tob Res"},{"key":"R27-8-20210203","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archpsyc.55.8.683","article-title":"Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.","volume":"55","author":"Hall","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R29-8-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00003495-199550020-00001","article-title":"Is clonidine an effective smoking cessation therapy?","volume":"50","author":"Gourlay","year":"1995","journal-title":"Drugs"},{"issue":"3","key":"R30-8-20210203","first-page":"CD000058","article-title":"Clonidine for smoking cessation.","author":"Gourlay","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R32-8-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pbb.2005.01.022","article-title":"Endocannabinoid system and alcohol addiction: pharmacological studies.","volume":"81","author":"Colombo","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"R33-8-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pbb.2005.01.024","article-title":"CB1 receptor antagonists for the treatment of nicotine addiction.","volume":"81","author":"Cohen","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"R34-8-20210203","first-page":"75","article-title":"Emerging treatment for diabetes, obesity, and smoking.","volume":"11","author":"Reynolds","year":"2005","journal-title":"US Pharmacist"},{"key":"R36-8-20210203","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2005.06.009","article-title":"Immunotherapy for the treatment of drug abuse.","volume":"108","author":"Kosten","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R37-8-20210203","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clpt.2005.08.007","article-title":"Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.","volume":"78","author":"Hatsukami","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R38-8-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjp.2008.30","article-title":"Neuropharmacology of alcohol addiction.","volume":"154","author":"Vengeliene","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"3","key":"R39-8-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ADM.0b013e318156c26f","article-title":"Acamprosate in alcohol dependence: implications of a unique mechanism of action.","volume":"1","author":"Littleton","year":"2007","journal-title":"J Addict Med"},{"key":"R40-8-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1472-8206.2006.00459.x","article-title":"Preclinical and clinical pharmacology of alcohol dependence.","volume":"21","author":"Tambour","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"R41-8-20210203","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","article-title":"Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.","volume":"24","author":"Johnson","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"R42-8-20210203","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0741-8329(90)90010-A","article-title":"Ethanol and the NMDA receptor.","volume":"7","author":"Hoffman","year":"1990","journal-title":"Alcohol"},{"key":"R43-8-20210203","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1176\/ajp.155.6.726","article-title":"Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal.","volume":"155","author":"Tsai","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R44-8-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1196\/annals.1300.010","article-title":"NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.","volume":"1003","author":"Krystal","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"R45-8-20210203","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram. A half century later.","volume":"26","author":"Suh","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R46-8-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","article-title":"Does disulfiram have a role in alcoholism treatment today?","volume":"99","author":"Fuller","year":"2004","journal-title":"Addiction"},{"key":"R47-8-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/02791072.1988.10472495","article-title":"The clinical use of disulfiram (Antabuse): a review.","volume":"20","author":"Banys","year":"1988","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"R48-8-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005053-197112000-00002","article-title":"Disulfiram treatment of alcoholism.","volume":"153","author":"Lundwall","year":"1971","journal-title":"J Nerv Ment Dis"},{"key":"R49-8-20210203","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","article-title":"Pharmacological treatment of alcohol dependence. A review of the evidence.","volume":"281","author":"Garbutt","year":"1999","journal-title":"JAMA"},{"key":"R50-8-20210203","doi-asserted-by":"crossref","first-page":"444","DOI":"10.15288\/qjsa.1973.34.444","article-title":"Drug-induced attenuation of alcohol consumption: a review and evaluation of the claimed, potential or current therapies.","volume":"34","author":"Mottin","year":"1973","journal-title":"Q J Stud Alcohol"},{"issue":"11","key":"R51-8-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"key":"R52-8-20210203","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200014050-00001","article-title":"Does disulfiram help to prevent relapse in alcohol abuse?","volume":"14","author":"Brewer","year":"2000","journal-title":"CNS drugs"},{"key":"R53-8-20210203","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archpsyc.1973.01750360034004","article-title":"Disulfiram maintenance in outpatient treatment of alcoholism.","volume":"28","author":"Gerrein","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"R54-8-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0005-7967(76)90021-8","article-title":"Improvements in community-reinforcement approach to alcoholism.","volume":"14","author":"Azrin","year":"1976","journal-title":"Behav Res Ther"},{"key":"R55-8-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","article-title":"Disulfiram treatment of alcoholism.","volume":"161","author":"Chick","year":"1992","journal-title":"Br J Psychiatry"},{"key":"R56-8-20210203","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1080\/10826080500294890","article-title":"Pharmacotherapy of alcohol use disorders.","volume":"40","author":"Buonopane","year":"2005","journal-title":"Substance Use Misuse"},{"key":"R57-8-20210203","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study.","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R58-8-20210203","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence.","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R59-8-20210203","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","article-title":"Pharmacological treatment of alcohol dependence: a review of the evidence.","volume":"281","author":"Garbutt","year":"1999","journal-title":"JAMA"},{"key":"R60-8-20210203","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/alcalc\/36.6.544","article-title":"Naltrexone, a relapse-prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials.","volume":"36","author":"Streeton","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"R61-8-20210203","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"R62-8-20210203","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence.","author":"Srisurapanont","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R63-8-20210203","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/36.1.2","article-title":"Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism.","volume":"36","author":"Sinclair","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"R64-8-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11920-006-0040-0","article-title":"Choosing the right medication for the treatment of alcoholism.","volume":"8","author":"Pettinati","year":"2006","journal-title":"Current Psychiatry Reports"},{"issue":"3-4","key":"R65-8-20210203","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1369-1600.2006.00036.x","article-title":"Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.","volume":"11","author":"Oslin","year":"2006","journal-title":"Addict Biol"},{"key":"R66-8-20210203","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence.","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"R67-8-20210203","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2741\/1559","article-title":"The preclinical development of Medisorb naltrexone, a once a month long acting injection, for the treatment of alcohol dependence.","volume":"10","author":"Dean","year":"2005","journal-title":"Front Biosci"},{"issue":"1","key":"R68-8-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1300\/J069v19n01_06","article-title":"Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients.","volume":"19","author":"Pettinati","year":"2000","journal-title":"J Addict Dis"},{"key":"R69-8-20210203","first-page":"2174","article-title":"The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.","volume":"22","author":"June","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"R70-8-20210203","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence.","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"key":"R71-8-20210203","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.","volume":"56","author":"Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"R72-8-20210203","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.npp.1300657","article-title":"The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.","volume":"30","author":"Bachteler","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R73-8-20210203","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","article-title":"Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain.","volume":"36","author":"Gual","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"R74-8-20210203","first-page":"130A","article-title":"Naltrexone and acamprosate: meta-analysis of two medical treatments for alcoholism.","volume":"26","author":"Hopkins","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"R75-8-20210203","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euroneuro.2003.08.009","article-title":"Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.","volume":"13","author":"Mason","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"R76-8-20210203","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"R77-8-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.","volume":"40","author":"Mason","year":"2006","journal-title":"J Psychiatr Res"},{"key":"R78-8-20210203","first-page":"67","article-title":"Ability of baclofen in reducing alcohol craving and intake: II-Preliminary clinical evidence.","volume":"24","author":"Addolorato","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"R79-8-20210203","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/01.ALC.0000141640.48924.14","article-title":"Baclofen for alcohol dependence: a preliminary open-label study.","volume":"28","author":"Flannery","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"R80-8-20210203","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol"},{"issue":"10","key":"R81-8-20210203","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00023210-200519100-00005","article-title":"Recent advances in the development of treatment for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.","volume":"19","author":"Johnson","year":"2005","journal-title":"CNS Drugs"},{"issue":"9370","key":"R82-8-20210203","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomized controlled trial.","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"issue":"14","key":"R83-8-20210203","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial.","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"issue":"8","key":"R84-8-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00023210-200418080-00002","article-title":"Pharmacotherapy of alcohol dependence. A review of the clinical data.","volume":"18","author":"Mann","year":"2004","journal-title":"CNS Drugs"},{"key":"R85-8-20210203","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1530-0277.1994.tb00054.x","article-title":"Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.","volume":"18","author":"Sellers","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"key":"R86-8-20210203","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized clinical trial.","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"R87-8-20210203","first-page":"97","article-title":"Naltrexone in the treatment of alcoholism. Two-year follow results.","volume":"13","author":"Landabaso","year":"1999","journal-title":"Eur J Psychiatry"},{"key":"R88-8-20210203","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","article-title":"Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.","volume":"22","author":"Besson","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"R89-8-20210203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R90-8-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/alcalc\/agl007","article-title":"Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.","volume":"41","author":"Feeney","year":"2006","journal-title":"Alcohol Alcohol"},{"issue":"12","key":"R91-8-20210203","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1017\/S109285290001511X","article-title":"The neurobiology of substance and behavioral addictions.","volume":"11","author":"Grant","year":"2006","journal-title":"CNS Spectr"},{"key":"R92-8-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2307\/2137033","article-title":"Reducing the risk of AIDS through methadone maintenance treatment.","volume":"29","author":"Ball","year":"1988","journal-title":"J Health Soc Behav"},{"key":"R93-8-20210203","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","article-title":"A 33-year follow-up of narcotics.","volume":"58","author":"Hser","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"R94-8-20210203","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.4\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: detoxification and maintenance options.","volume":"9","author":"Kleber","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"R95-8-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1749-6632.1978.tb16769.x","article-title":"Medical complications in methadone patients.","volume":"311","author":"Kreek","year":"1978","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"R96-8-20210203","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjcard.2004.01.072","article-title":"Coronary artery disease and opioid use.","volume":"93","author":"Marmor","year":"2004","journal-title":"Am J Cardiol"},{"key":"R97-8-20210203","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-143-8-200510180-00028","article-title":"Prescribing methadone as an analgesic.","volume":"143","author":"Dart","year":"2005","journal-title":"Ann Intern Med"},{"key":"R98-8-20210203","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","article-title":"Torsade de pointes associated with very-high-dose methadone.","volume":"137","author":"Krantz","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"R99-8-20210203","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","author":"Mattick","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R100-8-20210203","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1001\/jama.1993.03500150065028","article-title":"The effects of psychosocial services in substance abuse treatment.","volume":"269","author":"McLellan","year":"1993","journal-title":"JAMA"},{"key":"R101-8-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0376-8716(01)00171-5","article-title":"Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.","volume":"65","author":"Farre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R102-8-20210203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00213-002-1027-0","article-title":"High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.","volume":"161","author":"Donny","year":"2002","journal-title":"Psychopharmacology"},{"key":"R103-8-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0379-0738(01)00454-6","article-title":"Deaths involving buprenorphine: a compendium of French cases.","volume":"121","author":"Kintz","year":"2001","journal-title":"Forensic Sci Int"},{"key":"R104-8-20210203","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1521-0391.2003.tb00552.x","article-title":"Pharmacologic treatments for heroin and cocaine dependence.","volume":"12","author":"Kleber","year":"2003","journal-title":"Am J Addict"},{"issue":"20","key":"R105-8-20210203","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence.","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"issue":"4","key":"R106-8-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"R108-8-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","article-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.","volume":"101","author":"Fischer","year":"2006","journal-title":"Addiction"},{"key":"R109-8-20210203","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.drugalcdep.2005.10.001","article-title":"Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution.","volume":"82","author":"Lejeune","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R110-8-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2005.09.038","article-title":"Novel pharmacotherapeutic targets for the management of drug addiction.","volume":"526","author":"Heidbreder","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"R111-8-20210203","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","article-title":"Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.","volume":"35","author":"Gonzalez","year":"1988","journal-title":"Drugs"},{"issue":"1","key":"R112-8-20210203","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence.","author":"Minozzi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"R113-8-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0376-8716(98)00152-5","article-title":"Improvement in naltrexone treatment compliance with contingency management.","volume":"54","author":"Preston","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"R114-8-20210203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0740-5472(96)00164-X","article-title":"Naltrexone plus group therapy for the treatment of opiate-abusing health-care professional.","volume":"14","author":"Roth","year":"1997","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"R115-8-20210203","first-page":"CD006140","article-title":"Sustained-release naltrexone for opioid dependence.","author":"Lobmaier","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R116-8-20210203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.2000.tb06677.x","article-title":"Development of novel medications for drug addiction. The legacy of an African shrub.","volume":"909","author":"Glick","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R117-8-20210203","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.","volume":"914","author":"Mash","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R118-8-20210203","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1749-6632.1998.tb08242.x","article-title":"Medication development of ibogaine as a pharmacotherapy for drug dependence.","volume":"844","author":"Mash","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R119-8-20210203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine.","volume":"8","author":"Alper","year":"1999","journal-title":"Am J Addict"},{"key":"R120-8-20210203","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0740-5472(94)90049-3","article-title":"A preliminary investigation of ibogaine: case reports and recommendations for further study.","volume":"11","author":"Sheppard","year":"1994","journal-title":"J Subst Abuse Treat"},{"issue":"1-2","key":"R121-8-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0006-8993(96)00739-1","article-title":"et alIbogaine neurotoxicity: a re-evaluation.","volume":"737","author":"Molinari","year":"1996","journal-title":"Brain Res"},{"key":"R122-8-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0099-9598(01)56018-6","article-title":"Ibogaine: a review.","volume":"56","author":"Alper","year":"2001","journal-title":"Alkaloids Chem Biol"},{"issue":"4","key":"R123-8-20210203","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.mehy.2006.02.050","article-title":"Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction.","volume":"67","author":"Maas","year":"2006","journal-title":"Med Hypotheses"},{"issue":"3","key":"R124-8-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0091-3057(03)00119-9","article-title":"Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.","volume":"75","author":"Maissoneuve","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"R125-8-20210203","doi-asserted-by":"crossref","first-page":"389","DOI":"10.31887\/DCNS.2007.9.4\/pkalivas","article-title":"Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity.","volume":"9","author":"Kalivas","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"R126-8-20210203","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1471-4159.1993.tb03181.x","article-title":"Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.","volume":"60","author":"Sulzer","year":"1993","journal-title":"J Neurochem"},{"key":"R127-8-20210203","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0024-3205(90)90132-B","article-title":"Cocaine inhibition of ligand binding at dopamine, norepinephrine (NAT) and serotonin transporters (SAT): a structure-activity study.","volume":"46","author":"Ritz","year":"1990","journal-title":"Life Sci"},{"key":"R128-8-20210203","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/381","article-title":"Cocaine self-administration in dopamine-transporter knockout mice.","volume":"1","author":"Rocha","year":"1998","journal-title":"Nat Neurosci"},{"key":"R129-8-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2003.08.061","article-title":"Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice.","volume":"479","author":"Rocha","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"R130-8-20210203","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.euroneuro.2003.08.008","article-title":"Pharmacological treatments for heroin and cocaine addiction.","volume":"13","author":"van den Brink","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"R131-8-20210203","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/jm960305h","article-title":"Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-(2-(diphenylmethoxy)ethyl)-and 1-(2-(bis(4-fluorophenyl) methoxy)ethyl)-4-(3-phenylpropyl) piperazines (GBR 12935 and GBR 12909).","volume":"39","author":"Matecka","year":"1996","journal-title":"J Med Chem"},{"key":"R132-8-20210203","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0014-2999(89)90363-4","article-title":"The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action.","volume":"166","author":"Anderson","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"R133-8-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(96)00718-2","article-title":"Hyperactivity and behavioural seizures in rodents following treatment with dopamine D1 receptor agonist A-86929 and ABT-431.","volume":"317","author":"Shiosaki","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"R134-8-20210203","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0376-8716(01)00205-8","article-title":"A screening trial of amantadine as a medication for cocaine dependence.","volume":"66","author":"Shoptaw","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R135-8-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugalcdep.2006.04.002","article-title":"A double-blind, placebo-controlled trial of amantadine, propanolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.","volume":"85","author":"Kampman","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R136-8-20210203","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00004714-200110000-00010","article-title":"Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial.","volume":"21","author":"Grabowski","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R137-8-20210203","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1360-0443.2003.00447.x","article-title":"Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.","volume":"98","author":"Shearer","year":"2003","journal-title":"Addiction"},{"key":"R138-8-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1369-1600.2007.00061.x","article-title":"New developments in the pharmacotherapy of cocaine abuse.","volume":"12","author":"Preti","year":"2007","journal-title":"Addict Biol"},{"key":"R139-8-20210203","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"R140-8-20210203","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","article-title":"Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.","volume":"66","author":"Brown","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R141-8-20210203","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.jcp.0000169419.38899.5b","article-title":"Aripiprazole in schizophrenia with cocaine dependence: a pilot study.","volume":"25","author":"Beresford","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R142-8-20210203","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study.","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"issue":"4","key":"R143-8-20210203","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/ajp.150.4.675b","article-title":"Disulfiram therapy in patients abusing cocaine and alcohol.","volume":"150","author":"Higgins","year":"1993","journal-title":"Am J Psychiatry"},{"key":"R144-8-20210203","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1360-0443.1998.9357137.x","article-title":"Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram.","volume":"93","author":"Carroll","year":"1998","journal-title":"Addiction"},{"key":"R145-8-20210203","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1360-0443.2000.95913355.x","article-title":"One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment.","volume":"95","author":"Carroll","year":"2000","journal-title":"Addiction"},{"issue":"2","key":"R146-8-20210203","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1360-0443.2000.9522198.x","article-title":"Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.","volume":"95","author":"Petrakis","year":"2000","journal-title":"Addiction"},{"issue":"3","key":"R147-8-20210203","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","article-title":"Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.","volume":"61","author":"Carroll","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"R148-8-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0006-3223(97)00506-4","article-title":"Chronic disulfiram treatment effects on intranasal cocaine administration: initial results.","volume":"43","author":"McCance-Katz","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"suppl 1","key":"R149-8-20210203","first-page":"S72","article-title":"DBH genotype in disulfiram treatment for cocaine dependence.","volume":"29","author":"Cubells","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"R150-8-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0165-0173(93)90008-N","article-title":"Neurotransmitter regulation of dopamine neurons in the ventral tegmental area.","volume":"18","author":"Kalivas","year":"1993","journal-title":"Brain Res Rev"},{"key":"R151-8-20210203","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0028-3908(99)00094-5","article-title":"The GABA (B) agonist CGP44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure.","volume":"8","author":"Brebner","year":"1999","journal-title":"Neuropharmacology"},{"issue":"14","key":"R152-8-20210203","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200464140-00004","article-title":"Agents in development for the management of cocaine abuse.","volume":"64","author":"Gorelick","year":"2004","journal-title":"Drugs"},{"key":"R153-8-20210203","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/alcalc\/37.5.478","article-title":"A potential role for GABA(B) agonists in the treatment of psychostimulant addiction.","volume":"37","author":"Brebner","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"R154-8-20210203","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4088\/JCP.v64n1207","article-title":"Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use.","volume":"64","author":"Shoptaw","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R155-8-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1360-0443.2005.00992.x","article-title":"A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments.","volume":"100","author":"Winhusen","year":"2005","journal-title":"Addiction"},{"key":"R156-8-20210203","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1046\/j.1360-0443.2003.00544.x","article-title":"Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.","volume":"98","author":"Gonzalez","year":"2003","journal-title":"Addiction"},{"key":"R157-8-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.07.003","article-title":"Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine-dependent methadone-treated patients.","volume":"87","author":"Gonzalez","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R158-8-20210203","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/syn.10278","article-title":"Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.","volume":"50","author":"Brodie","year":"2003","journal-title":"Synapse"},{"key":"R159-8-20210203","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/syn.20097","article-title":"Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and\/or cocaine addiction.","volume":"55","author":"Brodie","year":"2005","journal-title":"Synapse"},{"key":"R160-8-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.drugalcdep.2004.03.008","article-title":"A pilot trial of topiramate for the treatment of cocaine dependence.","volume":"75","author":"Kampman","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"R161-8-20210203","first-page":"CD002950","article-title":"Antidepressants for cocaine dependence.","volume":"2","author":"de Lima","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R162-8-20210203","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drugalcdep.2006.02.011","article-title":"A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.","volume":"84","author":"Johnson","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R163-8-20210203","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1176\/ajp.2007.164.7.1115","article-title":"Cocaine desire is reduced by N-acetylcysteine.","volume":"164","author":"LaRowe","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R164-8-20210203","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-006-0372-9","article-title":"The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats.","volume":"186","author":"Peters","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R165-8-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0893-133X(98)00085-2","article-title":"The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade.","volume":"20","author":"Ferraro","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R166-8-20210203","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11920-004-0018-8","article-title":"Recent advances in the pharmacotherapy of cocaine dependence.","volume":"6","author":"Dackis","year":"2004","journal-title":"Curr Psychiatry Rep"},{"key":"R167-8-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.npp.1300600","article-title":"A double-blind, placebo-controlled trial of modafinil for cocaine dependence.","volume":"30","author":"Dackis","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R168-8-20210203","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","article-title":"Vaccine pharmacotherapy for the treatment of cocaine dependence.","volume":"58","author":"Martell","year":"2005","journal-title":"Biol Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e3181a91655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:26:42Z","timestamp":1739356002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200909000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":160,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181a91655","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}